Investors are pouring money into innovative Chinese drug makers, hoping to profit from the sales of new drugs in the world’s second largest pharmaceuticals market. Photo: Shutterstock
Chinese start-up Everest Medicines raises US$310 million in Series C round to fund development of drugs pipeline
- Everest focuses on developing drugs in Asia by licensing development and commercialisation rights from innovators
- Funding from Janchor Partners, RA Capital, Hillhouse Capital, and Jiashan SDIC to help the development of eight potential drug candidates
Topic |
Pharmaceuticals
Investors are pouring money into innovative Chinese drug makers, hoping to profit from the sales of new drugs in the world’s second largest pharmaceuticals market. Photo: Shutterstock